Phase 2/3 Study Launches of COVID-19 Antibody Treatment

Vir Biotechnology, Inc. and GlaxoSmithKline plc announced on August 31, 2020, that the first patient was dosed last week in a phase 2/3 study with VIR-7831 (GSK4182136), a fully human anti-SARS-CoV-2 monoclonal antibody, for the early treatment of COVID-19 disease in patients who are at high risk of hospitalization.